Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tildrakizumab in dimethyl fumarate non-responders with moderate to severe chronic plaque psoriasis
2019-000817-35Phase 4Unknown
- Sponsor
- Almirall
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tildrakizumab in psoriasis and plaque psoriasis (2 arms), sponsored by Almirall. Primary endpoint: PASI 75 response. Status: unknown.
02
Drugs
tildrakizumab
03
Conditions
psoriasisplaque psoriasis
Beyond the preview
Go deeper on 2019-000817-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000817-35.